Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547255 · ClinicalTrials.gov registry record · Phase 4
Exparel Versus Bupivacaine in Post-operative Pain Control
A Phase 4 study of Liposomal Bupivacaine, sponsored by Case Western Reserve University.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT06547255 is a Phase 4 study of Liposomal Bupivacaine that has completed, run by Case Western Reserve University. The registered enrollment target is 82 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06547255, a Phase 4 study of Liposomal Bupivacaine, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized study to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine
Conditions Studied
Interventions
- DRUG Bupivacaine liposome injectable suspension
Study Locations (1)
Ohio
- Case Western Reserve University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06547255
The ClinicalTrials.gov registry entry for NCT06547255 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liposomal Bupivacaine appearing as the primary indexed condition, and to 1 intervention - of which Bupivacaine liposome injectable suspension is the first listed.
NCT06547255 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06547255 about?
NCT06547255 is a clinical study titled "Exparel Versus Bupivacaine in Post-operative Pain Control". This is a prospective, randomized study to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine
What is the current status of trial NCT06547255?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2024-08-21. Estimated completion is 2025-07-01.
What conditions does trial NCT06547255 study?
This clinical trial studies the following conditions: Liposomal Bupivacaine.
What interventions are being tested in trial NCT06547255?
The interventions under investigation include: Bupivacaine liposome injectable suspension (DRUG).
Who is sponsoring clinical trial NCT06547255?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547255 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.